Characteristics of the patients' cohort according to the LALA-94 and GRAALL trials.
| . | GRAALL . | LALA-94 . | All . | P . |
|---|---|---|---|---|
| Patients, N | 145 | 87 | 232 | |
| Median age, y (range) | 30 (16-59) | 28 (15-55) | 29 (15-59) | .2 |
| Age ≥ 35 y | 36% | 31% | 36% | .48 |
| WBC, 109/L, median (range) | 32 (0.9-645) | 71 (1.4-620) | 48 (0.9-645) | .01 |
| WBC ≥ 100 × 109/L, % | 26% | 41% | 32% | .03 |
| UK-ECOG high-risk, % | 61% | 64% | 61% | .68 |
| CNS involvement, % | 10% | 7% | 9% | .49 |
| Prephase sensitivity, % | 54% | NA | NA | NA |
| . | GRAALL . | LALA-94 . | All . | P . |
|---|---|---|---|---|
| Patients, N | 145 | 87 | 232 | |
| Median age, y (range) | 30 (16-59) | 28 (15-55) | 29 (15-59) | .2 |
| Age ≥ 35 y | 36% | 31% | 36% | .48 |
| WBC, 109/L, median (range) | 32 (0.9-645) | 71 (1.4-620) | 48 (0.9-645) | .01 |
| WBC ≥ 100 × 109/L, % | 26% | 41% | 32% | .03 |
| UK-ECOG high-risk, % | 61% | 64% | 61% | .68 |
| CNS involvement, % | 10% | 7% | 9% | .49 |
| Prephase sensitivity, % | 54% | NA | NA | NA |
NA indicates not applicable.